Setmelanotide Phase 3 Trial: POMC vs LEPR Deficiency
Body weight regulation involves intricate hormonal and neural signaling networks, in which the leptin-melanocortin pathway plays a central biological role. When rare biallelic genetic variants impair this pathway, individuals experience early-onset severe obesity driven by persistent, unmanageable hunger. In 2020, researchers published pivotal clinical data evaluating setmelanotide, an agonist targeting the melanocortin 4 receptor (MC4R), in The Lancet Diabetes & Endocrinology. This comparison explainer examines how outcomes differed between participants with pro-opiomelanocortin (POMC) deficiency and those with leptin receptor (LEPR) deficiency within the study design.
Targeting the Melanocortin Pathway in Rare Genetic Obesity
The MC4R pathway serves as a key regulator of energy balance and satiety. Under typical physiology, leptin binds to its receptor (LEPR), triggering the processing of POMC into active peptides that activate downstream MC4R neurons in the brain to reduce body weight. Severe, early-onset obesity can arise when biallelic variants disrupt either LEPR or POMC, severing normal communication upstream of the receptor.
Setmelanotide was designed as a targeted MC4R agonist to stimulate receptor signaling directly, bypassing these upstream genetic blocks. While public discussions surrounding melanocortin peptides often involve tanning agents, our educational reviews on POMC deficiency genetics and what melanotan peptides are explain how different compounds within this family target distinct receptor subtypes for entirely different medical purposes.
Study Architecture: The 1-Year Multi-Stage Design
The investigation evaluated setmelanotide across ten hospitals located in Canada, the USA, Belgium, France, Germany, the Netherlands, and the UK. Registered under ClinicalTrials.gov identifiers NCT02896192 and NCT03287960, enrollment took place between Feb 14, 2017, and Sept 7, 2018. Eligible participants were aged 6 years or older with diagnosed POMC or LEPR deficiency obesity.
The research employed a structured, multi-stage timeline:
- Initial Open-Label Phase: All enrolled participants received open-label setmelanotide for 12 weeks.
- Placebo-Controlled Withdrawal Sequence: Participants who demonstrated at least 5 kg of weight loss (or at least 5% if baseline weight was under 100 kg) entered an 8-week sequence comprising 4 weeks of blinded setmelanotide and 4 weeks of blinded placebo.
- Open-Label Continuation: Following the withdrawal period, participants continued with 32 additional weeks of open-label treatment, completing an evaluation period of approximately 1 year.
Comparing Weight Loss: POMC Versus LEPR Cohorts
The primary trial endpoint measured the proportion of participants in the full analysis set who achieved at least 10% weight loss compared with baseline at approximately 1 year. The full analysis set included all individuals who received at least one dose and underwent baseline assessment, comprising 10 participants in the POMC cohort and 11 participants in the LEPR cohort.
A comparison between the two groups revealed clear differences in response rates:
- POMC Deficiency Cohort: Eight out of 10 participants (80%) achieved at least 10% weight loss from baseline at approximately 1 year.
- LEPR Deficiency Cohort: Five out of 11 participants (45%) achieved at least 10% weight loss from baseline over the same duration.
While both groups demonstrated weight reductions, participants missing the upstream POMC peptide experienced a higher response rate at the primary 10% weight loss threshold than participants with LEPR defects.
Evaluating Hunger Scores Across Both Deficiencies
Hyperphagia, an unrelenting and severe sensation of hunger, represents one of the most debilitating aspects of genetic melanocortin disorders. To track this symptom, the study assessed a key secondary endpoint: mean percentage change in the most hunger score using an 11-point Likert-type scale at approximately 1 year on the therapeutic dose.
This hunger outcome was evaluated in an eligible subset of participants aged 12 years or older who demonstrated at least 5 kg of weight loss (or at least 5% in pediatric participants under 100 kg) during the initial 12 weeks and entered the withdrawal sequence. Seven participants were evaluated in the POMC cohort, and 7 participants were evaluated in the LEPR cohort. Both groups documented hunger reductions on this 11-point scale, supporting the drug's role in addressing hyperphagia in individuals who met the protocol criteria.
Safety Profiles and Skin-Related Adverse Events
Because melanocortin receptors also influence pigment cells, safety monitoring documented both systemic and dermatologic effects. In the phase 3 setmelanotide trial published in The Lancet Diabetes & Endocrinology, no serious treatment-related adverse events occurred in either group. However, common adverse events differed between the cohorts:
- Injection Site Reactions: Occurred in all 10 participants in the POMC group and all 11 participants in the LEPR group.
- Dermatologic Changes: Hyperpigmentation was documented in all 10 participants in the POMC cohort, whereas skin disorders were reported in 5 participants in the LEPR cohort.
- Gastrointestinal Symptoms: Nausea was reported in 5 participants in the POMC cohort and 4 participants in the LEPR cohort; vomiting occurred in 3 POMC participants.
The universal appearance of hyperpigmentation among POMC participants highlights how systemic MC4R agonists cross-react with skin pigment pathways, emphasizing the necessity of formal dermatologic oversight.
Critical Trial Limitations and Unanswered Questions
While the study generated pivotal data, several critical design limitations must be considered:
- Single-Arm, Open-Label Format: Aside from the 8-week withdrawal sequence, the trials relied on open-label administration without a parallel, long-term control group.
- Very Small Sample Sizes: With only 10 participants in the POMC arm and 11 in the LEPR arm, the small sample sizes reflect the rarity of these biallelic genetic mutations but limit broad statistical conclusions.
- Industry Sponsorship: The research received funding from Rhythm Pharmaceuticals, the developer of the drug.
- Strict Genetic Scope: The findings apply exclusively to confirmed biallelic LEPR or POMC deficiency obesity, not polygenic obesity or cosmetic body modification.
Anyone experiencing abnormal pigment shifts or severe metabolic symptoms should consult a board-certified physician or dermatologist. Unregulated melanotan compounds sold through online websites remain unapproved, lack safety oversight, and carry substantial medical risks that differ entirely from regulated, doctor-supervised therapies.
Sources
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.